Erratum : Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study

In the article entitled “Comparative evaluation of tocilizumab and itolizumab for treatment of severe COVID-19 in India: a retrospective cohort study”, following corrections should be not- ed as pointed out by readers. 1. Introduction “Some studies have shown promising results with itolizumab, but no randomized controlled trial has confirmed its effectiveness. Although itolizumab has a similar mechanism of action to tocilizumab, no available study compares the two drugs in the management of COVID-19.” should be replaced by “Some studies have shown promising results with itolizumab, but there are limited randomized controlled trials comparing itolizumab with tocilizumab or control in the management of COVID-19 [1,2].” 2. Discussion “First, it is the first study to compare itolizumab with tocilizumab in the treatment of COVID-19.” should be replaced by “First, we conducted this study on a large population as compared to previous studies [1,2].” 3. Table 2 The footnotes a) and b) in serious adverse event in should be corrected as a) High-grade fe- ver: 2, arrhythmia: 1; b) High-grade fever: 2, bronchospasm: 2, liver dysfunction: 1.